NeuroBo Pharmaceuticals | ARS: Annual Report to Security Holders
Apr 30 08:45 ET
NeuroBo Pharmaceuticals | DEF 14A: Definitive information statements
Apr 30 08:45 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
Apr 30 08:35 ET
NeuroBo Pharmaceuticals | EFFECT: Others
Apr 24 06:08 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Apr 17 08:34 ET
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation
Apr 16 16:36 ET
NeuroBo Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
Apr 12 16:09 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Apr 1 08:31 ET
NeuroBo Pharmaceuticals | 10-K: Annual report
Mar 28 22:26 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
Mar 28 08:05 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Mar 13 08:33 ET
NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Woodworth Marshall H
Mar 4 21:21 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
Mar 4 07:35 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Feb 29 08:33 ET
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation
Feb 14 08:56 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
Feb 1 08:31 ET
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash
Jan 18 00:00 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
Jan 9 00:00 ET
NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Submits Ind Application to the Fda for a Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity
Dec 28, 2023 00:00 ET
NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Dec 19, 2023 09:03 ET
No Data
No Data